HOT RADAR
industryHEAT 28.6°

AI CURATED HOT STORY · 11/17/2026

Isomorphic Labs Raises $5 Billion Series C to Advance AI Drug Discovery

3 reports archived3 independent sourcesupdated 11/17/2026, 22:57:02
Synthesis & Latest Updates
3 Sources Cross-Validated

Isomorphic Labs, the AI drug discovery company spun out of Alphabet, has closed a $5 billion Series C round co-led by Greenoaks and Sequoia Capital, with new investor a16z joining and Alphabet and all existing shareholders participating. This is the company's second billion-dollar raise in six months, following a $2.1 billion round in May 2026, bringing total funding to $7.1 billion. The proceeds will be used to advance its proprietary IsoDDE platform and push drug candidates into clinical trials.

The round underscores Isomorphic Labs' central role in AI for Science. Led by Nobel laureate Demis Hassabis, the company builds on DeepMind's AlphaFold and uses a combination of chemical simulation models for drug design. Its IsoDDE platform reportedly surpasses AlphaFold 3 in predicting drug binding and docking sites, and the company has achieved positive preclinical results in oncology and immunology, with partnerships with Eli Lilly, Novartis, and Johnson & Johnson. Funds will support foundational simulation model research, expansion of internal and partnered drug candidates, and global AI-driven bioengineering infrastructure.

This financing is one of the largest ever in AI drug discovery, signaling continued investor confidence in AI-driven pharma R&D. Isomorphic Labs will use the capital to accelerate candidates into clinical stages, moving AI from basic research to actual therapies. The deal is likely to intensify competition in the AI pharma space, attract more capital and talent, and validate AI's potential to shorten drug development timelines and reduce failure rates, setting a new benchmark for the biotech industry.

LATEST/Following its $5 billion Series C, Isomorphic Labs is accelerating its IsoDDE platform and drug pipeline toward clinical trials. With partnerships with Eli Lilly, Novartis, and J&J, and positive preclinical results in oncology and immunology, the funds will scale candidate programs and build global AI-driven bioengineering infrastructure.

Hourly heat curve

12 fully observed hours
Now
28.6
Peak
35.623:00
24h change
–

The line compares only sources observed throughout; gap hours are interpolated to keep the trend continuous.

Coverage timeline

Total 3 reports · Latest first
  1. TechCrunch AIT2·78 pts
    • The $5B Series C was co-led by Greenoaks and Sequoia, with a16z joining and all existing investors including GV, Capital G, Temasek and MGX participating
    • Its engine builds on DeepMind's AlphaFold and combines multiple chemistry simulation models for drug design
    • Positive preclinical results in oncology and immunology plus deals with Eli Lilly, Novartis and J&J; proceeds target clinical trial advancement